A 24-month, Multi-center, Open-label, Randomized, Controlled Trial to Investigate Efficacy, Safety and Evolution of Cardiovascular Parameters in de Novo Renal Transplant Recipients After Early Calcineurin Inhibitor to Everolimus Conversion.

Trial Profile

A 24-month, Multi-center, Open-label, Randomized, Controlled Trial to Investigate Efficacy, Safety and Evolution of Cardiovascular Parameters in de Novo Renal Transplant Recipients After Early Calcineurin Inhibitor to Everolimus Conversion.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Everolimus (Primary) ; Ciclosporin; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Registrational; Therapeutic Use
  • Acronyms ELEVATE
  • Sponsors Novare Pharmaceuticals; Novartis
  • Most Recent Events

    • 03 May 2017 Results of a subanalysis from the ELEVATE study comparing the renal function outcomes by the presence of preformed and de novo donor-specific antibody in kidney transplant recipients receiving everolimus vs standard calcineurin inhibitor, presented at the 2017 American Transplant Congress.
    • 03 May 2017 Results of subanalysis from ELEVATE trial assessing effect of Human leukocyte antigen (HLA)-DQ mismatch on efficacy outcome and renal function presented at the 2017 American Transplant Congress
    • 03 May 2017 Results of post hoc analysis assessing effect of everolimus regimen on graft outcomes presented at the 2017 American Transplant Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top